Dublin, Ireland – A promising experimental treatment for neurogenic orthostatic hypotension (nOH), a debilitating condition affecting patients with multiple system atrophy (MSA), has hit a dead end. Theravance Biopharma announced topline results from its Phase 3 CYPRESS study on Tuesday, revealing that ampreloxetine failed to demonstrate statistically significant efficacy. This setback has triggered a major restructuring at the company, including a 50% workforce reduction and the cessation of all research and development programs. The news underscores the challenges in developing effective therapies for rare neurological disorders like MSA, which currently have no cure and limited treatment options.
The failure of ampreloxetine represents a significant blow to Theravance, which had touted the drug as a potential “first-in-class” medicine. The company’s stock price reacted negatively to the announcement, reflecting investor concerns about its future prospects. The restructuring plan, announced alongside the clinical trial results, includes a strategic review that could lead to a sale of the company, according to a press release. A committee comprised of members of Theravance’s board of directors will oversee this process, exploring all available options to maximize shareholder value.
Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects the autonomic nervous system, which controls essential bodily functions like blood pressure, heart rate, and breathing. Patients with MSA often experience nOH, characterized by a sudden drop in blood pressure upon standing, leading to dizziness, lightheadedness, and even fainting. The National Institute of Neurological Disorders and Stroke (NINDS) estimates that MSA affects approximately 3 to 6 per 100,000 people. Currently, treatment for nOH associated with MSA is largely symptomatic, relying on off-label use of existing medications.
Ampreloxetine’s Mechanism and Clinical Trials
Ampreloxetine is a norepinephrine reuptake inhibitor, designed to increase levels of norepinephrine, a neurotransmitter that helps regulate blood pressure. By blocking the reuptake of norepinephrine, the drug aimed to enhance its concentration in the synapses, thereby improving blood pressure control in patients with nOH. The Phase 3 CYPRESS study, a pivotal trial for potential regulatory approval, evaluated the efficacy and safety of ampreloxetine in patients with symptomatic nOH due to MSA. The primary goal of the study was to assess the change in hypotension symptoms at week 8, using a standardized assessment scale.
However, Theravance reported that the study did not meet its primary endpoint, meaning the results were not statistically significant. While the company stated that ampreloxetine was generally well-tolerated, with a safety profile consistent with previous studies, the lack of efficacy proved decisive. Despite the disappointing outcome, Theravance intends to conduct a thorough analysis of the Phase 3 data and consult with external experts to determine if there is any remaining value in ampreloxetine that could be presented to regulatory authorities. This assessment is intended to inform the board committee’s strategic review.
This isn’t the first clinical setback for ampreloxetine. In 2021, the drug failed a Phase 3 study involving patients with Parkinson’s disease, pure autonomic failure, and MSA with symptomatic nOH. A subsequent open-label study suggested a potential benefit in MSA patients specifically, leading the Food and Drug Administration (FDA) to agree to a further Phase 3 trial focused solely on this population. That trial, initiated in 2023, was the one that recently reported negative results. Prior to the readout, Theravance executives had expressed optimism about ampreloxetine’s potential, even suggesting it could become a fresh standard of care for nOH in MSA patients and generate substantial revenue.
Restructuring and Financial Outlook
The failed trial and subsequent restructuring represent a significant turning point for Theravance Biopharma. The company is streamlining its operations and focusing its resources on Yupelri, a chronic obstructive pulmonary disease (COPD) medication marketed in partnership with Viatris. Theravance also receives financial benefits from milestone payments related to sales of GSK’s COPD and asthma drug, Trelegy. In 2022, the company sold its economic interest in Trelegy to Royalty Pharma for approximately $1.11 billion in upfront cash, plus potential future milestone payments tied to the drug’s sales.
Theravance anticipates that the restructuring will reduce operating expenses by approximately 60%, resulting in savings of around $70 million. According to Rick Winningham, Theravance’s CEO, the company remains financially stable, with an expected cash balance of roughly $400 million at the end of the first quarter of 2026, and an anticipated $100 million milestone payment from Trelegy sales in 2026. “With a profitable commercial product, an expected cash balance of approximately $400 million at the end of the first quarter of 2026, and the anticipated $100 million Trelegy milestone in 2026, we continue to have a strong set of assets,” Winningham stated in a prepared statement.
Impact on Patients with MSA
The failure of ampreloxetine is particularly disheartening for patients living with MSA and nOH. Currently, there are limited treatment options available to manage the debilitating symptoms of nOH, and the prospect of a new, targeted therapy had offered a glimmer of hope. While existing medications can provide some relief, they often approach with side effects and may not fully address the underlying cause of the condition. The lack of effective treatments underscores the urgent need for continued research into MSA and related autonomic disorders.
The search for effective therapies for MSA is ongoing, with researchers exploring various approaches, including gene therapy, neuroprotective agents, and novel pharmacological targets. Patient advocacy groups, such as the Multiple System Atrophy Coalition, play a crucial role in raising awareness, funding research, and providing support to individuals and families affected by this challenging disease.
The company’s future remains uncertain as it navigates this period of transition. The board committee’s review of strategic alternatives could result in a sale of the company, a licensing agreement, or other restructuring measures. The next key event to watch for is the outcome of this strategic review, which is expected to provide further clarity on Theravance’s long-term plans. The company is expected to provide an update on its progress in the coming months.
Key Takeaways:
- Theravance Biopharma’s ampreloxetine failed a Phase 3 trial for neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
- The company is undergoing a major restructuring, including a 50% workforce reduction and the end of all R&D programs.
- Theravance is focusing on its commercial products, Yupelri and Trelegy, and exploring strategic alternatives, including a potential sale.
- The failure of ampreloxetine is a setback for patients with MSA, who have limited treatment options for nOH.
The situation highlights the inherent risks in pharmaceutical development, particularly for rare diseases. While the path to bringing new therapies to market is fraught with challenges, continued investment in research and development is essential to improve the lives of patients with unmet medical needs.
Do you have thoughts on the challenges of developing treatments for rare diseases? Share your comments below, and please share this article with your network.
Related reading